Research & Education

Gilead Sciences Inc (GILD) Fair Value Analysis July 2026

2026-07-07 · fairvalue-calculator.com

By Dr. Peter Klein, BA · Founder

Gilead Sciences Inc (GILD) Fair Value Analysis

Gilead Sciences Inc (GILD) is a leading biopharmaceutical company focused on developing and commercializing medicines in HIV, oncology, and other therapeutic areas. As of July 7, 2026, the stock trades at USD 131.27. Our models calculate a fair value of USD 146.5, implying +11.6% upside and supporting an undervalued verdict with a Quality Score of 78/100.

Company Overview

Gilead’s core business centers on HIV treatments, where Biktarvy continues to dominate the U.S. market with over 52% share. Recent growth also stems from Trodelvy in oncology and the launch of Yeztugo for HIV prevention. In Q1 2026 the company reported product sales excluding Veklury up 8% year-over-year to $6.8 billion, driven by strong HIV performance and new product contributions.

Why Gilead Sciences Appears Undervalued on Our Model

Our fair value estimate of $146.5 incorporates conservative assumptions around revenue growth from the HIV franchise and emerging oncology pipeline. At the current price the stock offers an attractive entry point relative to projected cash flows and a quality profile that reflects durable competitive advantages in virology. The +11.6% upside to fair value reflects the market’s temporary focus on near-term accounting noise rather than long-term fundamentals.

Analysts have highlighted the company’s clean Q1 2026 beat—non-GAAP EPS of $2.03 versus estimates of $1.91—along with raised full-year revenue guidance. Despite these positives, the share price has remained range-bound near recent lows, creating the valuation gap our model identifies.

Key Valuation Drivers

HIV Franchise Durability: Biktarvy and the expanding PrEP opportunity provide predictable, high-margin revenue through at least 2036 with no major loss of exclusivity until then.
Oncology Pipeline Momentum: Trodelvy’s recent first-line approval in metastatic triple-negative breast cancer and additional launches planned for 2026 expand addressable markets.
Free Cash Flow Generation: The base business continues to deliver robust cash conversion that supports dividends and future R&D or tuck-in acquisitions.

To run your own scenarios on GILD or any of the 35,000+ stocks we cover, try our fair value calculator.

💡 Theory is good — numbers are better. Get the fair value of any stock worldwide in seconds. Try it free →

Main Risks to Consider

Acquisition Accounting Impact: A $11.5 billion acquired IPR&D charge is expected to produce a GAAP loss for 2026 even as the underlying business grows.
Integration and Execution: Multiple parallel integrations and four planned 2026 launches introduce operational complexity.
Competition and Policy: Ongoing pressure in HIV prevention adoption curves and broader healthcare reimbursement or policy risks remain watch items.

Balanced Verdict

Gilead Sciences Inc combines a high-quality HIV moat with meaningful oncology optionality. Our model views the current $131.27 price as offering a compelling risk-reward profile with 11.6% upside to the $146.5 fair value. Investors focused on durable cash flows and a Quality Score of 78/100 may find the setup attractive ahead of the August 6, 2026 earnings report.

Check the latest numbers and run custom scenarios for the free Fair Value Calculator to check Gilead Sciences Inc.

Frequently Asked Questions

Is Gilead Sciences stock undervalued in 2026?

Yes, our analysis shows GILD trading at a discount to its $146.5 fair value, offering 11.6% upside with a solid quality score of 78/100.

What are the main risks for Gilead Sciences investors?

Key risks include acquisition-related accounting charges, integration of new assets, competition in HIV and oncology, and potential regulatory or reimbursement pressures.

When is Gilead Sciences next earnings report?

Gilead is scheduled to report Q2 2026 earnings on August 6, 2026, following a strong Q1 beat and raised revenue guidance.

Sources

Context gathered via live web search while writing this article:

Educational analysis only — not financial advice and not a buy or sell recommendation. Valuations are model-based and may be wrong; past performance does not indicate future results.

Check the fair value of any stock worldwide
26 valuation models · 12,000+ stocks · evidence-based
Start free →

Not financial advice · No buy/sell recommendations · Past performance is not a guarantee of future results.